InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,697.81
(
1.42%
)
US TECH 100
19,306.00
(
2.38%
)
Dow Jones
41,947.58
(
1.07%
)
Brent Oil
73.85
(
2.02%
)
Bitcoin
62,929.23
(
2.05%
)
Post# of 253155
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gym gravity post# 68340

Tuesday, 11/11/2008 7:30:02 PM

Tuesday, November 11, 2008 7:30:02 PM

Post# of 253155
Re: Tidbits on the all-oral HCV cocktail

ITMN’s Dan Welch gave some tidbits on the INFORM-1 trial of ITMN-191 plus R7128 during today’s DB webcast:

1. The trial sites are in Australia and New Zealand because the FDA (and presumably the EMEA) did not approve of a trial with two experimental agents until each agent was already in phase-2. By mid 2009, each of the agents (ITMN-191 and R7128) will be in phase-2, allowing trials to begin in the US (and presumably in Europe).

2. Two-week results from INFORM-1 should be available in time for reporting at EASL in April.

3. After two weeks on ITMN-191 + R7128, patients will continue with 46 weeks of SoC (a total treatment duration of 48 weeks). Patients will be tested for RVR, EVR, and SVR. (Although two weeks of treatment with ITMN-191 + R7128 may be less than optimal, the above metrics, especially RVR and SVR, will nonetheless be considerable interest.)

4. The exact dosing protocol in the trial is being kept a secret (at Roche’s behest); however, Welch said at least four different ratios of the two drugs will be tested.

5. From the questions by the analysts on the webcast, it’s clear that INFORM-1 is a hot topic among those who follow the HCV arena with even a modicum of interest.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up